Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: Statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Trials, ISSN 1745-6215, E-ISSN 1745-6215, Vol. 18, nr 1, artikel-id 627Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Small trials have suggested that fluoxetine may improve neurological recovery from stroke. FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised, placebo-controlled trials which aim to determine whether the routine administration of fluoxetine (20 mg daily) for six months after an acute stroke improves patients' functional outcome. Methods/Design: The core protocol for the three trials has been published (Mead et al., Trials 20:369, 2015). The trials include patients aged 18 years and older with a clinical diagnosis of stroke and persisting focal neurological deficits at randomisation 2-15 days after stroke onset. Patients are randomised centrally via each trials' web-based randomisation system using a common minimisation algorithm. Patients are allocated fluoxetine 20 mg once daily or matching placebo capsules for six months. The primary outcome measure is the modified Rankin scale (mRS) at six months. Secondary outcomes include: living circumstances; the Stroke Impact Scale; EuroQol (EQ5D-5 L); the vitality subscale of the 36-Item Short Form Health Survey (SF36); diagnosis of depression; adherence to medication; serious adverse events including death and recurrent stroke; and resource use at six and 12 months and the mRS at 12 months. Discussion: Minor variations have been tailored to the national setting in the UK (FOCUS), Australia, New Zealand and Vietnam (AFFINITY) and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A prospectively planned individual patient data meta-analysis of all three trials will provide the most precise estimate of the overall effect and establish whether any effects differ between trials or subgroups. This statistical analysis plan describes the core analyses for all three trials and that for the individual patient data meta-analysis. Recruitment and follow-up in the FOCUS trial is expected to be completed by the end of 2018. AFFINITY and EFFECTS are likely to complete follow-up in 2020.

Ort, förlag, år, upplaga, sidor
BioMed Central Ltd. , 2017. Vol. 18, nr 1, artikel-id 627
Nyckelord [en]
Antidepressants, Depression, Fluoxetine, Haemorrhagic stroke, Ischaemic stroke, Recovery, SSRI, acute coronary syndrome, algorithm, Article, automutilation, brain hemorrhage, brain ischemia, cerebrovascular accident, clinical protocol, cognition, death, drug effect, falling, fracture, functional status, gastrointestinal hemorrhage, health economics, health status, human, hyperglycemia, hypoglycemia, hyponatremia, medication compliance, meta analysis, mood, neurologic disease, outcome assessment, quality of life, Rankin scale, recurrent disease, seizure, Short Form 36, side effect, suicide attempt, survival, treatment duration, treatment outcome, upper gastrointestinal bleeding
Nationell ämneskategori
Neurologi
Identifikatorer
URN: urn:nbn:se:kth:diva-227107DOI: 10.1186/s13063-017-2385-6ISI: 000419147400010PubMedID: 29282099Scopus ID: 2-s2.0-85039552548OAI: oai:DiVA.org:kth-227107DiVA, id: diva2:1205904
Forskningsfinansiär
Vetenskapsrådet
Anmärkning

QC 20180515

Tillgänglig från: 2018-05-15 Skapad: 2018-05-15 Senast uppdaterad: 2019-02-07Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Näsman, Per

Sök vidare i DiVA

Av författaren/redaktören
Näsman, Per
Av organisationen
KTH
I samma tidskrift
Trials
Neurologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 25 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf